Excellent care for people with suspected infections involves rapid diagnosis and treatment. In this modern age, we still do not have the technology available and diagnostic methods often take at least two days to produce results, which is too slow to help clinicians. The rapid detection of bacteria, fungi, mycobacteria and their differentitation from viral pathogens would likely improve treatment outcomes and health utilisation resources by guiding treatment decisions at the time and place where they are taken.
RAPP-ID will develop a Point-of-Care Test (POCT) for rapid detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods in hospital patients in less than 2 hours and for outpatients in less than 30 minutes. The platforms will also determine resistance to antimicrobial drugs.
The research will focus on pathogens and host biomarkers involved in:
1) Blood Stream Infections
2) Lower Respiratory Tract Infections (LRTI), including Community-Acquired Pneumonia (CAP) and Ventilator-Associated Pneumonia (VAP)
3) Tuberculosis (TB)
RAPP-ID aims to provide an integrated solution that addresses the technological challenges to enhance clinical decision-making and improve the quality of care and clinical outcomes for the people of Europe and worldwide.